FLAMINGO Trial Reaches Major Milestone in Breast Cancer Treatment Development

Greenwich LifeSciences Inc. (GLSI) has demonstrated strong momentum in its clinical pipeline as the company advances its investigational immunotherapy for breast cancer. The recently announced preliminary results from a key patient population in the FLAMINGO trial have sparked investor interest and validated the potential of the company’s approach to treating this prevalent disease.

FLAMINGO Trial Demonstrates Significant Promise in HER2-Positive Breast Cancer Patients

The FLAMINGO-01 study, a phase III clinical trial, has shown encouraging preliminary findings from its 250-patient open-label arm focused on patients who are not HLA-A*02-positive. Results indicated an approximately 80% reduction in cancer recurrence rate—a substantial clinical outcome for breast cancer patients at high risk of disease relapse following standard surgical and medical treatments.

Roughly 75% of breast cancer cases express HER2/neu, a cell surface receptor protein that drives cancer cell proliferation. For this significant patient population, recurrence prevention remains a critical treatment objective. The FLAMINGO trial enrolled HLA-A*02-positive and HER2/neu-positive patients who had completed both neoadjuvant and post-operative standard therapies, positioning the study to evaluate outcomes in patients with high recurrence risk.

The overall trial design includes approximately 500 HLA-A*02-positive patients randomized to receive either GLSI-100 or placebo, plus up to 250 additional patients with other HLA types receiving the active treatment in an open-label format. This multi-arm structure allows researchers to assess both efficacy and patient population specificity.

GLSI-100 Mechanism: Harnessing Immune Recognition Against Breast Cancer

GLSI-100 represents a combination immunotherapy strategy pairing a GP2 peptide vaccine with GM-CSF, an immune system activator. The therapeutic approach aims to prime the body’s immune system to recognize and eliminate cancer cells expressing the HER2/neu protein. Beyond breast cancer, HER2/neu expression appears across multiple cancer types, potentially broadening the addressable patient population.

The FLAMINGO trial specifically targets breast cancer patients at elevated recurrence risk who have already received standard-of-care chemotherapy and surgical intervention. By administering immunotherapy after conventional treatments, the approach seeks to provide a maintenance effect that reduces cancer re-emergence.

Strategic Trial Modifications Aim to Accelerate FLAMINGO Outcomes

Pending regulatory approval, Greenwich LifeSciences intends to implement several modifications to optimize the FLAMINGO study. These changes include expanding the overall patient enrollment to enhance statistical robustness, a strategy that accounts for potentially fewer observed recurrence events than historical assumptions while maintaining trial integrity.

The company plans to accelerate enrollment rates substantially—potentially doubling or quadrupling current pace—to accumulate patient-years more rapidly and achieve key trial milestones more efficiently. Additionally, continued enrollment beyond interim analyses will maintain momentum across active clinical sites, while independent committee recommendations could trigger trial resizing or timeline adjustments based on emerging data.

A commercially manufactured batch of GP2 drug product will be incorporated into the ongoing trial, ensuring consistency with anticipated commercial manufacturing processes. The projected completion date for FLAMINGO-01 remains December 31, 2026, according to ClinicalTrials.gov.

Financing Strategy and Market Position Amid Trial Progress

Greenwich LifeSciences held $3.81 million in cash as of September 30, 2025, and has deployed an at-the-market (ATM) offering strategy to preserve capital efficiency. Between January and September 2025, the company completed ATM stock offerings via H.C. Wainwright, selling 621,674 shares at an average price of $10.44 per share and generating $6.49 million in gross proceeds.

The company’s board extended the lock-up period for insider and pre-IPO shareholder holdings until September 30, 2026—approximately 72 months following the company’s September 25, 2020 initial public offering at $5.75 per share. Stock price momentum has accelerated recently, with the shares reaching a 52-week intraday high of $22.31 on December 26, 2025, before closing that session at $20.68.

Competitive Landscape: Positioning GLSI-100 Within Breast Cancer Therapies

The breast cancer treatment ecosystem includes multiple major pharmaceutical players shaping therapeutic options. Roche markets HER2-targeted approaches including Herceptin, Perjeta, and Kadcyla; AstraZeneca and Daiichi Sankyo jointly developed Enhertu; Pfizer markets Ibrance; Gilead Sciences offers Trodelvy; Novartis developed Kisqali; and Merck markets Keytruda across oncology indications.

This competitive landscape creates both challenges and partnering opportunities. Greenwich LifeSciences actively engages with potential collaborators at industry conferences, positioning GLSI-100 as a complementary immunotherapeutic approach. Larger pharmaceutical companies frequently acquire or partner with clinical-stage developers demonstrating promising breast cancer efficacy data, particularly within the substantial HER2-positive patient population.

With more than 4 million breast cancer survivors currently in the United States according to the American Cancer Society, and approximately 75% of new breast cancer cases expressing HER2, the addressable market for HER2-directed therapies remains substantial. Success in the FLAMINGO trial could position Greenwich LifeSciences for meaningful commercial or partnership developments as the company advances this investigational immunotherapy.